Targeting health-related quality of life in patients with myelodysplastic syndromes – Current knowledge and lessons to be learned

• Published in: Blood reviews Vol. 50; p. 100851
• Main Authors: Oliva, Esther N., Platzbecker, Uwe, Fenaux, Pierre, Garcia-Manero, Guillermo, LeBlanc, Thomas W., Patel, Bhumika J., Kubasch, Anne Sophie, Sekeres, Mikkael A.
• Format: Journal Article
• Language: English
• Published: England Elsevier Ltd 01.11.2021
• Subjects: Erythrocyte Transfusion - methods; Health-related quality of life; Humans; Myelodysplastic syndromes; Myelodysplastic Syndromes - diagnosis; Myelodysplastic Syndromes - therapy; Patient-reported outcomes; Prognosis; Quality of Life; Health-related quality of life; Myelodysplastic syndromes; Patient-reported outcomes
• ISSN: 0268-960X; 1532-1681
• DOI: 10.1016/j.blre.2021.100851

Using a range of health-related quality of life (HRQoL) instruments, most – but not all – studies of myelodysplastic syndromes (MDS) have reported that lower hemoglobin levels and red blood cell transfusion dependency are associated with worse HRQoL. In addition, some MDS treatments may significantly improve HRQoL, particularly among those patients who respond to therapy; however, the majority of these studies were underpowered for this secondary endpoint. Furthermore, decreased HRQoL has been associated with worse survival outcomes, and HRQoL scores can be used to refine classical prognostic systems. Despite the subjective nature of HRQoL, the importance and validity of measuring it in trials and clinical practice are increasingly being recognized, but properly validated MDS-specific instruments are required. We describe what is currently known about HRQoL in patients with MDS, and the limitations of measuring HRQoL, and we provide some recommendations to improve the measurement of this outcome in future trials.